NAA Services for Anti-CAGE
Creative Biolabs is a highly focused research-driven company and has many years of experience and high-end technologies in NAA (natural autoantibodies) research. We have successfully developed a series of innovative and diversified NAA platforms to provide fast and convenient services for our worldwide customers. Various NAA products are now available for researches at Creative Biolabs. With our unbeatable product portfolio of anti-CAGE marker services for diseases diagnosis and therapeutic monitoring, we will help you to do a better career your NAA projects.
Background of Anti-CAGE Antibody
The cancer-associated gene (CAGE) is a human gene which was originally isolated by serological analysis of a cDNA expression library (SEREX) with serum from a patient with gastric cancer. CAGE is a cancer/testis antigen that has the notable property of being immunogenic in cancer patients and is considered to be a promising target for cancer vaccines due to its restricted expression pattern. Hypomethylation of CAGE directly increases the expression of CAGE, and thereby displays oncogenic potential and regulates the expression of cyclins. It is known that CAGE is widely expressed among cancer cell lines and cancer tissues, yet restricted to testis tissue among normal tissues. Because of the limitation of CAGE expression pattern, it is considered as a promising cancer vaccine target. Anti-CAGE antibodies have also been shown to be suitable for payload delivery, particularly, anti-CAGE antibodies can be applied for oncology combining with cytotoxic agents that have limited selectivity.
The Role of Anti-CAGE Antibody in Lung Cancer
Lung cancer (LC) is the largest cause of cancer-related mortality worldwide, killing around 900, 000 people every year. LC such as diagnosed during routine medical care is rapidly fatal; even clinical stage I tumors are at high risk of relapses after complete surgical resection. There is a considerable body of evidence documenting the presence of circulating antibodies to autologous cellular antigens in serum samples from patients with a variety of cancers, including LC. Monitoring the levels of certain serum autoantibodies of persons at increased risk of cancer may allow earlier detection of the disease. The CAGE is involved in many bioactive processes, including RNA processing, ribosome assembly, spermatogenesis, embryogenesis, cell growth, and division, and may well be important in the carcinogenic pathway. Moreover, CAGE, together with other cancer/testis antigens or antigens (such as Anti-NY-ESO-1, GBU4-5, and Anti-p53), have been demonstrated in plenty of solid tumors to induce the production of autoantibodies in LC. CAGE seems to be immunogenic and cancer-specific, and antibodies specific against CAGE may provide diagnostic and therapeutic value as potentially immunotherapeutic cancer targets.
Fig.1 Molecular mechanisms of infection and pathogenesis of lung cancer. (Tsyganov, et al., 2019)
What We Can Do About NAA?
As an antibody expert in this field, Creative Biolabs has a wide spectrum of NAA products is available for your choice. Aided by our well-established platforms and specialized scientists, we also provide comprehensive NAA services, from NAA detection, NAA profiling, to NAA epitope mapping. Our proven and optimized platforms can help you quickly achieve satisfactory results in the shortest time and at the least cost. Our experts will help you with the NAA development of anti-CAGE marker services for diseases diagnosis and therapeutic monitoring.
If you are interested in our services, please contact us for more details.
Reference:
- Tsyganov, M. M.; et al. Human papillomavirus and lung cancer: an overview and a meta-analysis. Journal of Cancer Research and Clinical Oncology. 2019, 145(8): 1919-1937.
Related Services:
- NAA Services for Anti-p53
- NAA Services for Anti-MUC1 Antibody
- NAA Services for Anti-HER2
- NAA Services for Anti-c-Myc Antibodies
- NAA Services for Anti-GBU4-5